We are thrilled to announce that SilicoGene has been selected to participate in the highly regarded AWS Build Accelerator. This 10-week program is designed to help startups like ours make critical strategic decisions related to product development while leveraging the full power of the AWS tech stack. Throughout the program, we’ll work alongside AWS experts and industry leaders to build and launch our MVP, refining our product and taking it to market with confidence.
The AWS Build Accelerator is specifically tailored for early-stage, tech-focused startups that are ready to transition from ideation to building a refined Minimum Viable Product (MVP). Over the course of the program, startups like SilicoGene will dive deep into best practices for product development, covering key topics such as Leveraging the AWS tech stack, Strategic product decisions and Cloud technology fundamentals.
“Being part of the AWS Build Accelerator program is an exciting opportunity for SilicoGene. Being accepted into an accelerator program by a company like Amazon demonstrates the great potential of our idea and has truly motivated our team from the start,” said Hossein Kamar, founder of SilicoGene.
Over the next 10 weeks, SilicoGene will focus on maximizing the potential of our MVP with the expert guidance provided by the AWS Build Accelerator. We are excited about the learning, development, and growth opportunities ahead and look forward to sharing updates on our progress. Stay tuned as we continue our journey toward launching our MVP and bringing innovative solutions to pharma industry.
We are grateful to our partners and supporters for their continued belief in our vision. Your support is integral to our success, and we look forward to taking SilicoGene to new heights with the AWS Build Accelerator.
